Biomaterials

Bellamy N, Bell MJ, Pericak D, Goldsmith CH, Torrance GW, Raynauld JP, Walker V, Tugwell P, Polisson R. 2007. BLISS index for analyzing knee osteoarthritis trials data. J Clin Epidemiol 60:124-132.

Hunziker E, Spector M, Libera J, Gertzman A, Woo SL, Ratcliffe A, Lysaght M, Coury A, Kaplan D, Vunjak-Novakovic G. 2006. Translation from research to applications. Tissue Eng 12:3341-3364.

Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld JP, Torrance GW, Tugwell P, Polisson R. 2005. Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. Ann Rheum Dis 64:881-885.

Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld JP, Torrance GW, Tugwell P, Polisson R. 2005. The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: an application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI. Osteoarthritis Cartilage 13:104-110.

Burns JW, Kraines JL, Magilavy DB, Murray CW, Richards SM. 2005. Response to: Identification of an immunogenic candidate for the elicitation of severe acute inflammatory reactions (SAIRs) to hylan G-F 20. Osteoarthritis Cartilage.

Cohen Z, Senagore AJ, Dayton MT, Koruda MJ, Beck DE, Wolff BG, Fleshner PR, Thirlby RC, Ludwig KA, Larach SW, Weiss EG, Bauer JJ, Holmdahl L. 2005. Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioresorbable membrane: A prospective, randomized, evaluator-blinded multicenter study. Dis Colon and Rectum 48:1130-1139.

Gianolio DA, Philbrook M, Avila LZ, MacGregor H, Duan SX, Bernasconi R, Slavsky M, Dethlefsen S, P.K. J, Miller RJ. 2005. Synthesis and evaluation of hydrolyzable hyaluronan-tethered bupivacaine delivery systems. Bioconjug Chem 16:1512-1518.

Johnston EE, Bryers JD, Ratner BD. 2005. Plasma deposition and surface characterization of oligoglyme, dioxane, and crown ether nonfouling films. Langmuir 21:870-881.

Kemper F, Gebhardt U, Meng T, Murray C. 2005. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin 21:1261-1269.

Raynauld JP, Goldsmith CH, Bellamy N, Torrance GW, Polisson R, Belovich D, Pericak D, Tugwell P. 2005. Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis. Osteoarthritis Cartilage 13:111-119.

Sikkink CJJM, Reijnen MMPJ, Falk P, Van Goor H, Holmdahl L. 2005. Influence of monocyte-like cells on the fibrinolytic activity of peritoneal mesothelial cells and the effect of sodium hyaluronate. Fertility and Sterility 84(SUPPL. 2):1072-1077.

Bellamy N, Bell M, Goldsmith C, Pericak D, Walker V, Raynauld JP, Torrance G, Tugwell P, Polisson R. 2004. Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. Ann Rheum Dis.

Magilavy DB, McPherson JM, Polisson R. 2004. Pseudoseptic reactions to Hylan viscosupplementation: diagnosis and treatment. Clin Orthop Relat Res:349-350; author reply 350-351.

Miller RJ, Avila LZ. 2004. Medicinal uses of modified hyaluronate. In: Garg HG, Hales CA, editors. In: Chemistry & Biology of Hyaluronan: Elsevier. p 505-528.

Shiedlin A, Bigelow R, Christopher W, Arbabi S, Yang L, Maier RV, Wainwright N, Childs A, Miller RJ. 2004. Evaluation of hyaluronan from different sources: Streptococcus zooepidemicus, rooster comb, bovine vitreous, and human umbilical cord. Biomacromolecules 5:2122-2127.

Magilavy D, Polisson R, Murray C. 2003. Acute local reaction to intra-articular Hylan G-F 20 (Synvisc): part I. J Bone Joint Surg Am 85-A:1618-1619; author reply 1619-1620.

Magilavy D, Polisson R, Parenti D. 2003. Re: Karlsson et al. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford) 42:1262; author reply 1262-1263.

Ruiz-Perez B, Cisneros RL, Matsumoto T, Miller RJ, Vasios G, Calias P, Onderdonk AB. 2003. Protection against lethal intra-abdominal sepsis by 1-(3-dimethylaminopropyl)-3-ethylurea. J Infect Dis 188:378-387.

Chegini N, Zhao Y, Kotseos K, Ma C, Bennett B, Diamond MP, Holmdahl L, Skinner K. 2002. Differential expression of matrix metalloproteinase and tissue inhibitor of MMP in serosal tissue of intraperitoneal organs and adhesions. Bjog 109:1041-1049.

Hubbard SC, Burns JW. 2002. Effects of a hyaluronan-based membrane (Seprafilm) on intraperitoneally disseminated human colon cancer cell growth in a nude mouse model. Dis Colon Rectum 45:334-341; discussion 341-334.

Jackson JK, Skinner KC, Burgess L, Sun T, Hunter WL, Burt HM. 2002. Paclitaxel-loaded crosslinked hyaluronic acid films for the prevention of postsurgical adhesions. Pharm Res 19:411-417.

Chegini N, Kotseos K, Ma C, Williams RS, Diamond MP, Holmdahl L, Skinner K. 2001. Differential expression of integrin alpha v and beta 3 in serosal tissue of human intraperitoneal organs and adhesion. Fertil Steril 75:791-796.

Polisson R. 2001. Innovative therapies in osteoarthritis. Curr Rheumatol Rep 3:489-495.

Reijnen MM, Skrabut EM, Postma VA, Burns JW, van Goor H. 2001. Polyanionic polysaccharides reduce intra-abdominal adhesion and abscess formation in a rat peritonitis model. J Surg Res 101:248-253.